Navigation Links
Cytochroma Closes $45 Million Series C Financing
Date:7/30/2008

Proceeds to Advance Clinical Development Of Lead Drug Candidates

MARKHAM, ON, July 30 /PRNewswire/ - Cytochroma today announced the closing of a CDN $45 million Series C financing. The financing was led by a new investor, Mitsubishi Tanabe Pharma Corporation ("MTPC"), and supported by a number of existing investors including Vengrowth Advanced Life Sciences Fund Inc., Caisse de Depot et Placement du Quebec, Novo A/S, Canadian Medical Discoveries Fund Inc., T(2)C(2)/Bio 2000 Limited Partnership, GrowthWorks Canadian Fund Ltd., BDC Capital Inc., and VentureLink Brighter Future Fund Inc.

Charles W. Bishop, PhD, Cytochroma's President and CEO stated, "We are grateful for the strong support of MTPC and our existing investors as we work to achieve our goal of becoming an integrated specialty pharmaceutical company. This latest funding provides Cytochroma with the financial capability to aggressively drive the development of our clinical-stage therapeutic pipeline."

The new funding will be used to advance Cytochroma's portfolio of vitamin D-based therapeutics into mid- and late-stage clinical trials. Cytochroma's product candidates target disorders related to altered vitamin D metabolism in chronic kidney disease ("CKD") patients, and include CTA018 and CTAP201 for the treatment of secondary hyperparathyroidism ("SHPT"), and CTAP101 for the treatment of vitamin D insufficiency. These three lead products address significant markets that are expected to grow to more than $1.4 billion annually by 2013 in North America.

In connection with the financing, Seiichi Kiso, PhD, MBA, General Manager, Business Development & Licensing Department of MTPC, and Joseph Regan, GrowthWork's Vice President, Investments, have joined Cytochroma's Board of Directors bringing the number of directors to six. Elizabeth Douville, PhD, Vice President of GeneChem Management Inc., has retired from the Board after more than nine years of service with the Company.

<
'/>"/>
SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cytochroma Appoints R. Richard Wieland II As CFO
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
4. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
5. AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury
6. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
7. MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
8. Raptor Pharmaceuticals Closes $10 Million Private Placement
9. China Pharma Holdings, Inc. Closes $10 Million Financing
10. Transdel Pharmaceuticals Closes $4 Million Financing
11. Dilon Technologies Closes First Quarter With Record Sales

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... SANMATEO,Calif.,Nov.24/PRNewswire-FirstCall/--Neu...nyfocusedondevelopingandcommercializingnovelpainma...,PresidentandChiefExecutiveOfficer,isscheduledtopr...ce,tobeheldDecember1-2,2009atTheNewYorkPalaceHotel...ieri,ChiefFinancialOfficer,willbeavailabletorespon...
(Date:11/24/2009)...,Primaryefficacyendpointhasbeenmetforpatientswitha... QUEBECCITY,Nov.24/PRNewswire-FirstCall/-AEternaZe...lobalbiopharmaceuticalcompanyfocusedonendocrinethe...fromaPhase2studywithitstargetedcytotoxicpeptidecon...ncedorrecurrentendometrialcancer.Inapersonalizedhe...
(Date:11/24/2009)... REDWOODCITY,Calif.,Nov.24/PRNewswire-FirstCall/--...tRandyScott,GenomicHealth,sExecutiveChairman,willp...nceinNewYorkCityonTuesday,December1,2009at10:00a.m...ebcastofthepresentation,visittheInvestorRelationss...enomichealth.com .Pleaseconnecttothewebsiteatleast...
(Date:11/24/2009)... SEATTLE,Nov.24/PRNewswire-FirstCall/--CellTherape...esentatthe21stAnnualPiperJaffrayHealthCareConferen...wYorkPalaceHotel. ,, CTIwillpresentonTuesday,De...liveaudiowebcastofCTI,spresentationwillbeavailable...bleforreplayafterwards. , ,PiperJaffrayHealthCare...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...y shows median overall survival of 27.5 months, ...ednisone and a 16.9, months overall surviv...evement of survival benefit milestone results in r...d shares of OGXI., , , BOTHELL, WA and VANCOU...rmaceuticals, Inc. (NASDAQ: OGXI ) today announc...
...oes are like Typhoid Mary. They can spread viruses...low fever without themselves getting sick. Scienti...ther it had a virus hitchhiker, but have now disco...n, assistant professor of entomology at Virginia T...the host and invading RNA the strands of code tha...
...Alfred E. Mann Foundation for,Biomedical Engineeri...by,billionaire Alfred E. Mann to establish univers... at elite universities, designed to facilitate bio...iety, today announced the launch of,a Web site ( h...eb site include: , -- Overview of Alfred Man...
Other Biology Technology:OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Virginia Tech researchers discover how mosquitoes avoid succumbing to viruses they transmit 2Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market 2
(Date:11/24/2009)...markable class of ring-shaped protein motors has b...keley National Laboratory (Berkeley Lab) using a s...t the Advanced Light Source (ALS). These protein m...plication, and are vital to the survival of all bi... as the human papillomavirus, which has been linke...
(Date:11/24/2009)...09) New research on bacterial communities through...ictable temporal patterns, suggesting that scienti...itoring climate change in the polar regions. The s...he National Academy of Sciences Early Edition, sh...hifted synchronously over time, correlating with s...
(Date:11/23/2009)...The time of day matters to forest trees dealing wi... research team led by Professor Malcolm Campbell, ... for research and colleagues in the department of ... , Capitalizing on their previous work to deco...m examined how poplar trees use their 45,000 genes...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Time of day matters to thirsty trees, U of T researcher discovers 2Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 56420 1Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 56420 2Yoga Can Ease Lower Back Pain 56417 1Yoga Can Ease Lower Back Pain 56417 2Yoga Can Ease Lower Back Pain 56417 3Reportlinker Adds Lung Cancer Therapeutics Report 56414 1Reportlinker Adds Lung Cancer Therapeutics Report 56414 2Reportlinker Adds Lung Cancer Therapeutics Report 56414 3Reportlinker Adds Lung Cancer Therapeutics Report 56414 4Reportlinker Adds Lung Cancer Therapeutics Report 56414 5Reportlinker Adds Lung Cancer Therapeutics Report 56414 6Reportlinker Adds Lung Cancer Therapeutics Report 56414 7Reportlinker Adds Lung Cancer Therapeutics Report 56414 8Reportlinker Adds Lung Cancer Therapeutics Report 56414 9Reportlinker Adds Lung Cancer Therapeutics Report 56414 10
... gene variation appears to significantly increase ...ver will go on to develop hepatocellular carcinoma...use of cancer death. In the January 2 Journal of ... Massachusetts General Hospital (MGH) Cancer Cente... single alteration in the epidermal growth factor ...
...ndent papers in the January 1st issue of G&D repor...d microRNA (miRNA) locus in Drosophila. The studie...T) and colleagues, and from Dr. Eric Lai (MSKCC) a...ption of the Hox miRNA locus, miR-iab-4, generates...cessed into active regulatory RNAs. When ectopical...
...c. 28, 2007) -- A research team at Weill Cornell M... genes that may be crucial to the production of an...10). , The discovery fills in an important "mis...en tied to disorders ranging from lupus and Type 1...n has to be kept in a delicate balance for health,...
Other Biology News:Gene variation may elevate risk of liver tumor in patients with cirrhosis 2Gene variation may elevate risk of liver tumor in patients with cirrhosis 32 genes are important key to regulating immune response 22 genes are important key to regulating immune response 3
Heated Processing Chamber from Terra Universal, Inc.
Down Draft Work Station from Terra Universal, Inc.
...acker Intracellular Localization Kit provides a st...ver siRNA, of your design, in an efficient yet non...ents. Subcellular localization and functional inhi...following introduction of the labeled siRNA into m...
Corning Cryo Box For Internal Thread Vials Only,100 Position,1-2 ml,Non-Sterile from Sigma-Aldrich
Biology Products: